Monoclonal antibody 3F8
Alternative Names: 3F8 MAb; MAb-3F8; MOAB 3F8; Murine 3F8 monoclonal antibodyLatest Information Update: 24 Oct 2021
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Neuroblastoma
Most Recent Events
- 10 Mar 2010 Phase-II development is ongoing in USA
- 31 Dec 2007 Monoclonal antibody 3F8 licensed to United Therapeutics Corporation worldwide
- 31 Jan 2007 Memorial Sloan-Kettering Cancer Center initiates enrolment in a phase II trial for neuroblastoma in the US